IPO Week Preview

October 12–16, 2026 | Research observation: 2026-10-12T11:48:37Z

By Frank Whitaker and Stan Rosenberg Research and information gathered by staff

INFORMATION GATHERED BY STAFF — COMPLETE MONDAY–FRIDAY CALENDAR

The week-ahead specialist calendar identifies two conventional U.S. operating-company IPOs. The first-trade dates are estimates, not exchange confirmations. The precise pricing days, final share prices and final allocations have not been established. A broad calendar may also include SPAC securities, direct listings or other instruments; none is promoted into this conventional-IPO list without corroboration.

IPO MARKET VOICES

An October 8 Wall Street Journal article described renewed biotech underwriting activity, citing investment-bank figures for 23 biotech IPOs in the first three quarters of 2026. That is a published market observation, not evidence of a speech delivered on October 12. The same reporting relayed commentary from Nasdaq and banking professionals about investor appetite and the quality of biotech candidates. Their optimism is useful context; it is not an assurance about either offering here. The exact dates of underlying interviews have not been independently established.

Reuters' October 9 week-ahead account described an upcoming stretch of bank earnings and inflation data against a backdrop of high Treasury yields. Those are not IPO events, but they matter: investors comparing a speculative drug company with other uses of cash pay attention to the price of money. No new Fed or SEC statement specific to these two issuers was verified in this research pass.

THIS WEEK'S IPOs IN THE NEWS

Iambic Therapeutics: Reuters, October 8, reported the company's launch of a proposed offering and the role of AI in its drug-development platform. The story also named pharma collaborations and potential cornerstone interest. https://www.reuters.com/legal/litigation/nvidia-backed-iambic-therapeutics-targets-up-806-million-valuation-us-ipo-2026-10-08/

Iambic Therapeutics: SEC, October 8, published an amended preliminary registration statement with the 9,375,000-share offer and $15–$17 range. This is primary company filing material, not independent journalism. https://www.sec.gov/Archives/edgar/data/1997038/000119312526417416/iam-20261008.htm

City Therapeutics: Renaissance Capital, October 9, included the RNA-interference developer in its two-company week-ahead calendar, with a proposed $175 million raise. https://www.renaissancecapital.com/IPO-Center/News/122164/us-ipo-week-ahead-biotech-remains-a-bright-spot-in-a-2-ipo-week

City Therapeutics: SEC, September 24, recorded the company's public S-1 filing, which identifies its Cambridge headquarters and CEO Andrew Orth. https://www.sec.gov/Archives/edgar/data/2143850/000110465926110430/tm2619715-5_s1.htm

NOTES FROM FRANK — WHO ARE WE BEING ASKED TO BACK?

I started with the calendar and found myself staring at two companies that are both called biotech. That's a little like saying two shops sell food. It tells me the neighborhood, not what I'm getting for dinner.

Iambic is in San Diego. It began in 2019 under the name Entos, and its current chief executive is Thomas Miller. The company has spent years building a system that uses artificial intelligence alongside automated chemistry and biology to help design small-molecule medicines. The computer is not the medicine. The computer helps the researchers decide which molecules to make and test. That's a distinction worth keeping in mind when every other headline seems to have AI stamped on the box.

Its lead program is aimed at cancers involving HER2 changes. It is in an early human trial. A trial is a beginning, not a pharmacy shelf. Patients, doctors and regulators still need evidence that a treatment works and that its risks are acceptable. I wanted to know what the money was buying. At the $16 midpoint, 9,375,000 shares would bring in $150 million before underwriting costs and other expenses. That's a substantial amount of money, but drug development can swallow a substantial amount of money without promising a product at the end.

There is something else here that caught my attention. Reuters reports collaborations with AbbVie and Takeda. Those names suggest established pharmaceutical companies see a reason to work with Iambic. They do not tell us that the lead drug will succeed, or that every potential partnership dollar will be collected. I'd want to read the actual arrangements before treating a partnership headline like cash in the bank.

City Therapeutics, over in Cambridge, Massachusetts, is taking a different route. Its approach is RNA interference, which tries to quiet the production of particular proteins involved in disease. I can understand that better if I think of a factory: instead of waiting for a troublesome product to come off the assembly line, researchers are trying to reduce the instruction that tells the factory to make it. The biology is far more complicated than my factory, of course. But the idea helps explain why this is not simply another version of Iambic.

City's programs touch thromboembolic disease, Stargardt disease and anemia associated with chronic illness. The lead program is in a Phase 1 study in healthy volunteers, with the company expecting data later this year. The SEC filing identifies Andrew Orth as chief executive and a Cambridge address at 399 Binney Street. Its public S-1 arrived September 24. That gives us a real filing milestone, but it does not reveal the whole earlier private regulatory preparation timeline.

At the $18 midpoint, the planned 9,722,222 shares work out to about $175 million gross. I keep coming back to the same question: how far does that take the science? It would be a mistake to treat $175 million as the price of a finished treatment. Investors are paying to finance a long stretch of work in which some questions may be answered and others may become harder.

I also went looking for a reliable company website for City during this pass, but I did not independently establish an official domain. I won't guess one. Iambic's website is listed by Renaissance Capital as https://iambic.ai. Both companies' filings are more important than a polished website when we're checking the offering terms.

NOTES FROM STAN — WHAT ARE WE BUYING, EXACTLY?

Frank wants to know the people. Fine. I want to know what the share buys. Two companies, $325 million of planned gross proceeds between them at their midpoints, and neither has a finished product described in this calendar. That's not a criticism. That's the stage of the businesses. But let's not compare them with profitable drug manufacturers and pretend the exercise means something.

Iambic is asking us to put a value on a combination of laboratory work, software, scientists, trial assets and future possibilities. City is asking us to put a value on a different technology and different diseases. They may both sit in the biotech aisle, but they are not the same item on the shelf. If a comparison can't survive that first distinction, it doesn't belong in the story.

Start with the share math. Iambic's indicated $15 to $17 range means roughly $140.6 million to $159.4 million in gross proceeds on the stated shares. City's $17 to $19 range implies about $165.3 million to $184.7 million. Those are arithmetic ranges, not estimates of net cash after expenses. They also aren't valuations. A company's market capitalization depends on all shares outstanding after the deal, not merely the new shares sold to the public.

Renaissance Capital estimates Iambic around $809 million and City around $1 billion in market capitalization at the proposed midpoints. Those are preliminary indications. I'd want the full post-offering share count, outstanding options, preferred-stock conversion, underwriter over-allotment and any later share issuance before calling either number the last word on ownership.

And where do the businesses stand with customers? A clinical-stage biotech is not a software subscription company. Collaboration partners and clinical research relationships aren't the same as recurring sales of an approved medicine. Iambic has reported pharmaceutical partnerships. That's real information, but the terms and recognition of revenue matter. City has a clinical pipeline, not a demonstrated mass market for an approved product. So please, spare me a giant theoretical market figure until somebody can explain which patients could actually receive the treatment, what it would cost, who would pay and what other medicines are already competing for those patients.

I've seen the comparison temptation before. Last week's TRex Bio and Retension Pharmaceuticals offerings are fresh evidence of the reception for early-stage biotech. Renaissance Capital's October 11 review says TRex finished its debut flat relative to its offer and Retension ended the week down about 12%. That's useful context for market mood, not a prediction for this week's names. Different trial stages, diseases, float and deal terms can make two biotech IPOs behave very differently. I'm not going to invent a six-month return for an IPO that hasn't traded for six months.

The broader market isn't helping anyone make an easy call. Treasury yields and inflation expectations have been pressing valuations. If investors can earn more on less speculative assets, the promised future cash from a drug that might reach market years from now gets examined more carefully. The arithmetic isn't glamorous. It is still arithmetic.

Grandpa worked in a steel mill for a time and taught me that putting money into an ownership claim meant giving up the chance to spend that dollar today. The memory fits here. A biotech share is not a prescription for future wealth. It's a claim on a business whose researchers still have important work ahead of them. I'd rather ask an awkward question now than discover later that the answer was sitting in the prospectus all along.

WHAT WE KNOW / WHAT WE DON'T KNOW YET

We know: Two specialist-calendar IPO candidates, their indicative share counts and price ranges, their stated research focus, Iambic's October 8 amended SEC filing, City's September 24 SEC filing, and the lead bookrunners identified in the week-ahead preview.

We don't know yet: Final pricing, confirmed trading commencement, actual allocations, net proceeds, full updated capitalization, exact underwriter over-allotment exercise, later clinical outcomes or whether either offering will be postponed. City's official website was not independently verified in this pass. No fully matched historical comparable with verified longer-term return checkpoints was established, so none is presented as a statistical analogue.

SOURCES AND READER LINKS

• Renaissance Capital week ahead: https://www.renaissancecapital.com/IPO-Center/News/122164/us-ipo-week-ahead-biotech-remains-a-bright-spot-in-a-2-ipo-week
• Iambic SEC S-1 amendment Oct 8: https://www.sec.gov/Archives/edgar/data/1997038/000119312526417416/iam-20261008.htm
• City SEC S-1 Sept 24: https://www.sec.gov/Archives/edgar/data/2143850/000110465926110430/tm2619715-5_s1.htm
• Reuters Iambic Oct 8: https://www.reuters.com/legal/litigation/nvidia-backed-iambic-therapeutics-targets-up-806-million-valuation-us-ipo-2026-10-08/
• Renaissance IPO calendar: https://stockanalysis.com/ipos/calendar/
• Renaissance prior biotech IPOs: https://www.renaissancecapital.com/IPO-Center/Winners-Losers/1546
• Reuters market Oct 9: https://www.reuters.com/business/wall-st-week-ahead-bank-earnings-cpi-headline-busy-markets-week-sp-500-hovers-2026-10-09/
• Wall Street Journal biotech IPO market: https://www.wsj.com/pro/venture-capital/biotech-ipos-charge-ahead-as-tech-deals-stall-989b34b9